此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia

2026年4月29日 更新者:Istituto Giannina Gaslini

Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia: a Double-blind, Randomized, Placebo-controlled Trial

Celiac disease in children is frequently associated with iron deficiency and/or iron deficiency anemia due to intestinal malabsorption and chronic inflammation. Although a gluten-free diet is the standard treatment and can restore iron balance over time, there is currently no clear evidence or consensus on the role and timing of iron supplementation in pediatric patients at diagnosis.

Given the potential impact of anemia on growth and neurodevelopment, strategies that enable a faster correction of iron deficiency are clinically relevant. Sucrosomial® iron has shown improved absorption and gastrointestinal tolerability compared to conventional oral iron in adult celiac patients.

This study aims to evaluate whether Sucrosomial® iron supplementation, in addition to a gluten-free diet, is more effective and safe than diet alone in achieving a faster normalization of hemoglobin and iron stores in children with newly diagnosed celiac disease.

The primary objective of this randomized, double-blind, placebo-controlled, parallel-group study is to assess whether oral supplementation with Sucrosomial® iron, when added to a gluten-free diet (GFD), accelerates the normalization of iron stores and hemoglobin levels compared with GFD alone in school-age children and adolescents newly diagnosed with celiac disease presenting with hypoferritinemia and/or iron deficiency anemia.

Target Study Population: Children and adolescents with celiac disease and iron deficiency or anemia due to iron deficiency.

Study Duration Total study duration (per patient) will be about 6 months; total treatment duration (per patient) will be 6 months.

Number of Patients: 60 planned Two typologies of patients will be included: with hypoferritinemia and with anemia due to iron deficiency.

The randomization process will be stratified, so that:

  • 15 patients with hypoferritinemia receive active treatment and 15 patients receive placebo;
  • 15 patients with anemia due to iron deficiency receive active treatment and 15 patients receive placebo.

The age of patients will also be considered for the randomization (to assign the correct number of product bottles).

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Italy
      • Genova、Italy、意大利、16143
        • 招聘中
        • IRCCS Istituto Giannina Gaslini, pad 16
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Diagnosis of CD according to the current European ESPGHAN guidelines (clinical or histological) with confirmed hypoferritinemia or iron deficiency anemia.
  2. Age at diagnosis of CD between 8 and 18 years (inclusive).
  3. Absence of oral martial supplementation in the 30 days before the diagnosis and intravenous martial supplementation in the 90 days prior to the diagnosis of CD.
  4. Patients who have not already started GFD before diagnosis.
  5. Exclusion of other causes of anemia.
  6. Patients (and parents/legal guardian) able to understand and willing to participate in the study, with collaborative attitude.
  7. Informed consent release by both parents/legal guardian.

Exclusion Criteria:

  1. Potential celiac disease.
  2. Hb < 8 g/dL at screening
  3. Other causes of anemia, hemoglobinopathies or coagulopathies.
  4. Active bleeding or surgery or major trauma in the last 6 months.
  5. Other inflammatory diseases, neoplasms or IgE mediated food allergies
  6. Syndromes or presence of vascular malformations
  7. Pregnant or lactating patients (based on self-certification by the parents and by the patient, where applicable)*
  8. Patients with known or suspected allergy or hypersensitivity to the study products or any of their excipients.
  9. Taking oral iron-based medications in the 30 days prior to diagnosis and intravenous iron-based medications in the 90 days prior to diagnosis.
  10. Use of other investigational drug(s) within 30 days before study entry or during the study.
  11. Any other condition, illness or treatment that in the Investigator's opinion does not make the patient suitable for the study.

    • Self-certification of non-pregnancy status is considered sufficient given that the product under study is a safe and well-tolerated dietary supplement that has already been tested in pregnant women.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Sideral forte® VERUM drops for oral intake in addition to GFD

Patients with hypoferritinemia (no anemia):

  • From 8 years until development (Tanner stage <=3): 1 ml of Sideral forte® VERUM drops, equal to 14 mg of iron element;
  • From development (Tanner stage >3) up to 18 years: 2 ml of Sideral forte® VERUM drops, equal to 28 mg of iron element.

Patients with anemia due to iron deficiency:

  • From 8 years until development (Tanner stage <=3): 2 ml of Sideral forte® VERUM drops, equal to 28 mg of iron element;
  • From development (Tanner stage >3) up to 18 years: 3 ml of SiderAL FORTE oral drops, equal to 42 mg of iron element.
安慰剂比较:Sideral forte® matching PLACEBO drops for oral intake in addition to GFD

Patients with hypoferritinemia (no anemia):

  • From 8 years until development (Tanner stage <=3): 1 ml/day of PLACEBO drops;
  • From development (Tanner stage >3) up to 18 years: 2 ml/day of of PLACEBO drops.

Patients with anemia due to iron deficiency:

  • From 8 years until development (Tanner stage <=3): 2 ml of PLACEBO drops;
  • From development (Tanner stage >3) up to 18 years: 3 ml of PLACEBO drops.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time to normalization of iron status
大体时间:From enrollment to the end of the treatment at 6 months

Time from baseline (defined as the time from diagnosis of celiac disease) to the first documented normalization of iron status.

Normalization is defined as:

  • hemoglobin (Hb) within age- and sex-specific reference ranges in participants with iron deficiency anemia at baseline, or
  • serum ferritin within reference ranges in participants with isolated hypoferritinemia at baseline

Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.

From enrollment to the end of the treatment at 6 months

次要结果测量

结果测量
措施说明
大体时间
Change in hemoglobin
大体时间:Baseline to 6 months
Change in hemoglobin (Hb) levels (gr/dl) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in serum ferritin
大体时间:Baseline to 6 months
Change in serum ferritin levels (ng/ml) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in mean corpuscular volume (MCV)
大体时间:Baseline to 6 months
Change in mean corpuscular volume (MCV) (fL) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in mean corpuscular hemoglobin (MCH)
大体时间:Baseline to 6 months
Change in mean corpuscular hemoglobin (MCH) (pg) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in mean corpuscular hemoglobin concentration (MCHC)
大体时间:Baseline to 6 months
Change in mean corpuscular hemoglobin concentration (MCHC) (g/L) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in reticulocyte count
大体时间:Baseline to 6 months
Change in reticulocyte count (reticulocyte/mmc) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in serum iron
大体时间:Baseline to 6 months
Change in serum iron levels (ug/dl) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in transferrin saturation
大体时间:Baseline to 6 months
Change in transferrin saturation (%) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in vitamin B12
大体时间:Baseline to 6 months
Change in vitamin B12 levels (pg/ml) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in folate
大体时间:Baseline to 6 months
Change in folate levels (ng/ml) from baseline to 6 months. Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.
Baseline to 6 months
Change in fatigue score assessed by PedsQL™ Multidimensional Fatigue Scale
大体时间:From enrollment to the end of the treatment at 6 months

Change from baseline to 6 months in fatigue, assessed using the PedsQL™ Multidimensional Fatigue Scale total score.

The PedsQL™ Multidimensional Fatigue Scale is a validated pediatric questionnaire available in age-appropriate versions. Scores range from 0 to 100, with higher scores indicating lower levels of fatigue.

Comparisons will be performed between participants receiving oral Sucrosomial® iron supplementation plus a gluten-free diet (GFD) and those receiving GFD alone.

From enrollment to the end of the treatment at 6 months
Changes from baseline in disease-specific quality of life measured by Coeliac Disease Dutch Questionnaire (CDDUX)
大体时间:From enrollment to the end of the treatment at 6 months
To evaluate the effect of oral supplementation with Sucrosomial® iron, as an add-on to a gluten-free diet (GFD), compared with placebo, on disease-specific quality of life in pediatric patients with celiac disease. Quality of life will be assessed using the Coeliac Disease Dutch Questionnaire (CDDUX). Scores will be transformed to a standardized 0-100 scale, with higher scores indicating better quality of life. Changes from baseline to each follow-up time point will be analyzed and compared between treatment groups.
From enrollment to the end of the treatment at 6 months
Changes from baseline in generic health-related quality of life measured by Pediatric Quality of Life Inventory (PedsQL™ 4.0)
大体时间:From enrollment to the end of treatment (6 months)
To evaluate the effect of oral supplementation with Sucrosomial® iron, as an add-on to a gluten-free diet (GFD), compared with placebo, on generic health-related quality of life in pediatric patients. Quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL™ 4.0). Scores will be transformed to a standardized 0-100 scale, with higher scores indicating better quality of life. Changes from baseline to each follow-up time point will be analyzed and compared between treatment groups.
From enrollment to the end of treatment (6 months)
Adherence to GFD
大体时间:From enrollment to the end of the treatment at 6 months

To evaluate the adherence to the GFD in patients without Sucrosomial® iron supplementation compared to placebo group.

The adherence to GFD and to treatment will be assessed with interview during visits and with dietary diary.

From enrollment to the end of the treatment at 6 months
Changes from baseline in gastrointestinal symptoms assessed with PedsQL™ 3.0 Gastrointestinal Symptoms Module score
大体时间:From enrollment to the end of the treatment at 6 months

To evaluate the modifications from baseline to each follow-up time point in the PedsQL™ 3.0 Gastrointestinal Symptoms Module score, and to compare the two treatment groups.

The PedsQL™ 3.0 Gastrointestinal Symptoms Module is a disease-specific instrument designed to evaluate gastrointestinal symptoms in pediatric patients. It is scored on a 0-100 scale, with higher scores indicating fewer gastrointestinal symptoms.

From enrollment to the end of the treatment at 6 months
Number and proportion of participants with treatment-related adverse events, graded according to CTCAE v5.0, during Sucrosomial® iron supplementation
大体时间:From enrollment to the end of the treatment at 6 months
To evaluate the safety of Sucrosomial® iron supplementation in pediatric patients with hypoferritinemia and/or iron deficiency anemia at the onset of celiac disease. Adverse events will be collected throughout the study period and classified by type, severity (graded according to CTCAE v5.0 criteria), and relationship to the treatment. Gastrointestinal adverse events (e.g., abdominal pain, diarrhea, constipation, nausea) will be specifically recorded. Data will be summarized as the number and proportion of participants experiencing: (1) any adverse event, (2) treatment-related adverse events, and (3) gastrointestinal adverse events. Serious adverse events will be reported separately.
From enrollment to the end of the treatment at 6 months

其他结果措施

结果测量
措施说明
大体时间
Changes from baseline in inflammatory biomarkers
大体时间:From enrollment to the end of the treatment at 6 months

Exploratory objectives and endpoints. To evaluate the effects of oral supplementation with Sucrosomial® iron as an add-on to the GFD in pediatric patients with hypoferritinemia and/or iron deficiency anemia at the onset of celiac disease on inflammatory biomarkers.

The inflammatory biomarkers (IL-6, IL-10, alpha TNF, serum zonulin) will be assessed from baseline to each time point, in the two treatment groups.

From enrollment to the end of the treatment at 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月23日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年4月2日

首先提交符合 QC 标准的

2026年4月29日

首次发布 (实际的)

2026年5月4日

研究记录更新

最后更新发布 (实际的)

2026年5月4日

上次提交的符合 QC 标准的更新

2026年4月29日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享时间框架

from the end of study to 10 years after the end of study

IPD 共享访问标准

Access to the Individual Participant Data (IPD) and supporting documentation will be granted to:

Members of the original research team, including the principal investigator and authorized study staff.

Qualified external researchers who submit a legitimate research proposal.

Regulatory authorities or ethics committees if required for oversight or audit purposes.

All individuals requesting access must demonstrate appropriate qualifications and agree to comply with relevant data protection and confidentiality regulations.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅